Payment overview · 2025
General Payments
$72,353.35
75 reported records · 4 companies
Healthcare provider profile · identity verified
Gary Blick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORWALK, CT · NPI 1598837957
Verified facts
What the public records show
CMS Open Payments records show Gary Blick, MD received $72,353.35 in general payments during 2025 across 75 reported records.
ViiV Healthcare Company accounted for 99.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Apretude, Arexvy, Dovato, Xyosted.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Xyosted by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Serostim by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nucala by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APRETUDE as an associated drug or biological on 20350 records involving 6296 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Apretude by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 544 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $72,161.79 | 99.7% | 69 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $126.70 | 0.2% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $45.07 | 0.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,300.00 | 19 |
| Consulting Fee | $9,100.00 | 2 |
| Travel and Lodging | $7,955.10 | 17 |
| Food and Beverage | $1,998.25 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $27,378.77 | 32 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $24,280.99 | 14 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $18,803.75 | 12 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| APRETUDE apretude |
2025 | Apretude | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 544 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 389 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
389 | 69 |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
95 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | APRETUDE open payments reported associated product |
CMS Open Payments — General Payments 20350 supporting records · 6296 recipient NPIs · example record 1189508910 |
Apretude · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
544 | 55 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dovato | Dolutegravir Sodium/Lamivudine | 544 | 55 |
| Xyosted | Testosterone Enanthate | 389 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 57 |
| Valacyclovir | Valacyclovir Hcl | 266 | 43 |
| Tadalafil | Tadalafil | 223 | 37 |
| Mounjaro | Tirzepatide | 196 | 41 |
| Alprazolam | Alprazolam | 159 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 26 |
| Montelukast Sodium | Montelukast Sodium | 123 | 23 |
| Lisinopril | Lisinopril | 120 | 15 |
| Synthroid | Levothyroxine Sodium | 103 | 17 |
| Ozempic | Semaglutide | 99 | 19 |
| Gabapentin | Gabapentin | 96 | 18 |
| Serostim | Somatropin | 95 | 12 |
| Losartan Potassium | Losartan Potassium | 88 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 85 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 14 |
| Bupropion Xl | Bupropion Hcl | 79 | 12 |
| Clonazepam | Clonazepam | 77 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 11 |
| Omeprazole | Omeprazole | 70 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | suppressed |
| Glimepiride | Glimepiride | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 11 |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 12 |
| Meloxicam | Meloxicam | 52 | 19 |
| Diazepam | Diazepam | 51 | 17 |
| Carvedilol | Carvedilol | 47 | suppressed |
| Valtrex | Valacyclovir Hcl | 46 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | suppressed |
| Anastrozole | Anastrozole | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 28 | suppressed |
| Menveo A-C-Y-W-135-Dip | Mening Vac A,c,y,w-135 Dip/Pf | 28 | 16 |
| Prezcobix | Darunavir/Cobicistat | 28 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Levocarnitine | Levocarnitine | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Nucala | Mepolizumab | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Tivicay | Dolutegravir Sodium | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lamivudine | Lamivudine | 18 | suppressed |
| Botox | Onabotulinumtoxina | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Adapalene | Adapalene | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Apretude | Cabotegravir | 15 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cialis | Tadalafil | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Androgel | Testosterone | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Cardura | Doxazosin Mesylate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Temazepam | Temazepam | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pifeltro | Doravirine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Reyataz | Atazanavir Sulfate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72,353.35 · 75 records | ViiV Healthcare Company | APRETUDE, AREXVY, CABENUVA, DOVATO, SHINGRIX, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Apretude play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Antares Pharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error